
HCAT Stock Forecast & Price Target
HCAT Analyst Ratings
Bulls say
Health Catalyst is in a strong position, as both its technology and professional services segments continue to drive revenue growth, with a particular focus on expanding up-market and leveraging advancements in AI and Ignite intelligence. However, challenges in the end market and a negative mix shift towards services could act as near-term headwinds, as well as a potential slowdown in M&A activity. Despite these risks, Health Catalyst has a strong track record of customer retention and the company is taking steps to effectively communicate its value proposition through new leadership, making it a promising investment opportunity in the healthcare data and analytics space.
Bears say
Health Catalyst is facing significant challenges due to its ongoing transformation and recent divestiture of Vitalware, leading to a decline in revenue and adjusted EBITDA in FY26. The company's FY26 guidance also reflects a high level of churn and down-sell risk among its DOS (Data Operating System) clients, making it difficult to predict future performance. Additionally, while the company is implementing cost-saving measures through its Project Nexus initiative, there is a risk of execution issues as they navigate the transformation. This, coupled with uncertainties surrounding the current business model and lack of clarity on future growth prospects, leads to a cautious outlook on the stock.
This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.
HCAT Analyst Forecast & Price Prediction
Start investing in HCAT
Order type
Buy in
Order amount
Est. shares
0 shares